Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

0.9075 +0.0775 (+9.34%)
Streaming Delayed Price Updated: 10:46 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allarity Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 Next >
News headline image
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
Via AB Newswire
Topics Government
News headline image
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Changes to Board of Directors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.